Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Advanced RG6501 (OpRegen®) Development in Partnership with Roche and GenentechPublished OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: SpineCompleted Key Activities to Support Planned Regulatory Interactions for OPC1 and VAC2Expanded Collaboration with Advanced BioMatrix for HyStem® Cell Drug Del...
Source: pharmiweb.com